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Background: In colorectal cancer (CRC), unresectable liver metastases are linked to poor prognosis. Systemic
chemotherapy with regimens such as FOLFOX (combination of infusional 5-fluorouracil, leucovorin and oxaliplatin)
is the standard first-line treatment. The SIRFLOX trial was designed to assess the efficacy and safety of combining
FOLFOX-based chemotherapy with Selective Internal Radiation Therapy (SIRT or radioembolisation) using yttrium-90
resin microspheres (SIR-Spheres®; Sirtex Medical Limited, North Sydney, Australia).
Methods/Design: SIRFLOX is a randomised, multicentre trial of mFOLFOX6 chemotherapy ± SIRT as first-line treatment
of patients with liver-only or liver-predominant metastatic CRC (mCRC). The trial aims to recruit adult chemotherapy-naïve
patients with proven liver metastases with or without limited extra-hepatic disease, a life expectancy of ≥3 months and a
WHO performance status of 0–1. Patients will be randomised to receive either mFOLFOX6 or SIRT +mFOLFOX6 (with a
reduced dose of oxaliplatin in cycles 1–3 following SIRT). Patients in both arms can receive bevacizumab at investigator
discretion. Protocol chemotherapy will continue until there is unacceptable toxicity, evidence of tumour progression,
complete surgical resection or ablation of cancerous lesions, or the patient requests an end to treatment. The primary
endpoint of the SIRFLOX trial is progression-free survival (PFS). Secondary endpoints include: PFS in the liver; tumour
response rate (liver and any site); site of tumour progression; health-related quality of life; toxicity and safety; liver
resection rate; and overall survival. Assuming an increase in the median PFS from 9.4 months to 12.5 months with the
addition of SIRT to mFOLFOX6, recruiting ≥450 patients will be sufficient for 80% power and 95% confidence.
Discussion: The SIRFLOX trial will establish the potential role of SIRT + standard systemic chemotherapy in the first-line
management of mCRC with non-resectable liver metastases.
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In colorectal cancer (CRC), liver metastases are linked
to poor prognosis – death and recurrence are frequently
attributable to liver metastases [1-3]. Surgical resection
of CRC liver metastases can result in cure, and produces
5-year survival of 27-39% and 10-year survival of 12-36%
[2,4,5], as opposed to median survival of approximately
9 months if untreated [6]. However, only 10-20% of pa-
tients with liver metastases from CRC are candidates for
such surgery [7-10], and intra-hepatic and extra-hepatic
relapse after liver resection is common [11].
Systemic chemotherapy is, therefore, used as first-line
treatment in patients with non-resectable liver metastases
[12-17], and in some cases can sufficiently down-size the
tumour burden in patients with previously inoperable liver
metastases so that they may be converted to candidates for
potentially curative resection [18,19]. Internationally accep-
ted first-line chemotherapy regimens for patients with
mCRC include FOLFOX (combination of bolus and infu-
sional 5-fluorouracil [5-FU], leucovorin [LV] and oxali-
platin) and FOLFIRI (combination of bolus and infusional
5-FU, LV and irinotecan). These regimens provide median
survival times of 16–20 months [15,20], and the addition
of biologic agents, such as bevacizumab and cetuximab, to
chemotherapy regimens may enhance progression-free
survival (PFS) and overall survival (OS) [17,21].
Selective Internal Radiation Therapy (SIRT or radioem-
bolisation) is an innovative radiation therapy for mCRC,
which involves the delivery of SIR-Spheres® (Sirtex Medical
Limited, North Sydney, Australia), that contain the β-
emitter yttrium-90, into the arterial supply of the liver.
These resin microspheres are delivered via a trans-femoral
hepatic artery catheter. In a randomised Phase II trial,
treatment of mCRC with SIRT plus first-line 5-FU/LV
chemotherapy resulted in a longer time-to-progression
(18.6 months) compared with 5-FU/LV chemotherapy
alone (3.6 months) [22]. A subsequent Phase I clinical trial
demonstrated that SIRT combined with FOLFOX4 sys-
temic chemotherapy had acceptable tolerability [23]. In
this trial of 20 patients with non-resectable liver meta-
stases from CRC, SIRT was administered on the third or
fourth day of the first cycle of first-line chemotherapy.
The dose-limiting toxicity was grade 3/4 neutropenia, and
the authors suggested the maximum tolerated dose of
oxaliplatin was 60 mg/m2 for the first three cycles, with
full-dose FOLFOX4 thereafter [23]. Although the primary
endpoint of this study was toxicity, the objective response
rate according to Response Evaluation Criteria In Solid
Tumours (RECIST) was 90%, two patients (10%) were
down-staged to undergo hepatic resection and median
PFS was 9.3 months [23].
These results suggest that the combination of SIRT
and FOLFOX systemic chemotherapy warrants further
investigation. Consequently, two open-label, randomised,controlled Phase III trials of mFOLFOX6 ± SIRT as
first-line treatment of patients with liver-only or liver-
predominant mCRC were designed with virtually identical
protocols (SIRFLOX and FOXFIRE). The primary endpoint
of SIRFLOX is a comparison between treatment arms
of PFS.
Methods/Design
The SIRFLOX study will be conducted in accordance
with the Declaration of Helsinki, and approval has been
obtained from the relevant ethics committees for each
participating centre (see Additional file 1 for a list). When
the results of the study are reported, CONSORT guide-
lines will be adhered to.
Eligible population
The inclusion and exclusion criteria for the SIRFLOX
study is summarised in Table 1.
Overview of study design
SIRFLOX is a randomised, multicentre study of mFOL-
FOX6 ± SIRT as first-line treatment of patients with
inoperable liver-only or liver-predominant mCRC. In
SIRFLOX, the aim will be to recruit a minimum of 450
patients at a minimum of 35 sites in Australia, Europe,
Israel, New Zealand and USA. Eligible patients are ran-
domised 1:1 to receive either systemic chemotherapy
with 5-FU/LV + oxaliplatin (FOLFOX; control arm) or
single-session whole liver SIRT + systemic chemotherapy
with 5-FU/LV + oxaliplatin (FOLFOX; intervention arm)
(Figure 1). All patients may also receive bevacizumab at
the investigator’s discretion.
Randomisation and stratification
When a patient is eligible to participate in the study,
randomisation, using the method of minimisation, will
be performed using a centralised Study Randomisation
Centre at the NHMRC Clinical Trial Centre at the
University of Sydney. Treatment will be allocated randomly
using the following stratification parameters: liver-only ver-
sus extra-hepatic metastases (at least 60% of recruited
patients will have liver-only metastases); the extent of
tumour involvement of the liver (classed as ≤25% or >25%
tumour involvement determined by CT scan, and based
upon the tumour involvement groupings used by Gray
et al. [24]); planned use of bevacizumab with chemother-
apy; and investigational centre.
Protocol treatment
Systemic chemotherapy must start within 28 days of ran-
domisation. Treatment cycles are described in Figure 2.
All patients will be monitored until death or for a mini-
mum of 5 years. Patients randomised to the intervention
arm will require a hepatic angiogram and a liver-to-lung
Table 1 Patient eligibility criteria for SIRFLOX study
Inclusion criteria Exclusion criteria
● Written informed consent provided. ● Evidence of ascites, cirrhosis, portal hypertension, main portal
venous tumour involvement or main portal venous thrombosis.
● Aged ≥18 years with histologically confirmed adenocarcinoma
of the colon or rectum (with or without the primary tumour in situ).
● Previous radiation therapy to the upper abdomen.
● Proven liver metastases. ● Non-malignant disease that renders patients unsuitable
for the study treatment.
● WHO performance status of 0–1. ● Grade >1 peripheral neuropathy (NCI-CTCv3).
● Life expectancy of ≥3 months. ● Previous dose-limiting toxicity associated with adjuvant
5-FU or oxaliplatin chemotherapy.
● Patients with additional limited extra-hepatic metastases in the lung or lymph
nodes (fewer than 5 nodules ≤1 cm diameter or a single nodule ≤1.7 cm
diameter in the lung, and lymph node involvement in a single anatomical
area <2 cm diameter) with the aim of these patients being <40% of the
total number of patients recruited (but not being excluded even if they
account for more than this proportion).
● Pregnancy or breast-feeding.
● Chemotherapy-naïve for mCRC, but previous adjuvant systemic
chemotherapy for primary CRC or neoadjuvant chemo-radiotherapy to
the pelvis more than 6 months before recruitment are permitted.
● Current or history of cancer other than adequately treated
non-melanoma skin cancer or carcinoma in situ of the cervix.
● Deemed suitable for either treatment regimen by the investigator. ● Allergy to non-ionic contrast agents.
● Adequate haematological, renal and hepatic function.
● Using an acceptable method of contraception.
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suitability to receive this treatment. The prescribed activ-
ity of SIR-Spheres will be determined from the patient’s
body surface area (BSA), the percentage tumour invol-
vement, and the magnitude of liver-to-lung shunting (see
Table 2).
The dose of bevacizumab administered in the study
will be according to standard institutional protocols
(usually 5–10 mg/kg) and should be infused on the first
day of each chemotherapy cycle, commencing with cycle
1 in the control arm. In the intervention arm, bevacizu-
mab should be withheld until at least cycle 4 to mitigate
the risk of additive toxicity should the non-targeted
delivery of SIR-Spheres to the gastrointestinal tract occur.
If non-targeted delivery is suspected, then gastroduodeno-
scopy will be undertaken before the initiation of bevacizu-
mab therapy. If gastroduodenoscopy reveals an ulcer with
biopsy-proven microspheres present, bevacizumab will be
withheld until resolution of the ulcer.
In both arms, if following treatment response the
patient is deemed a candidate for surgical resection, andFigure 1 Overview of SIRFLOX study design. Figure footnote: * Bevacizuthe patient undergoes surgical resection and/or complete
ablation of their primary and metastatic cancer, adju-
vant cycles of protocol mFOLFOX6 ± bevacizumab will be
continued for a minimum of 12 cycles (including pre-
operative cycles).
Outcome measures
The primary outcome measure of the SIRFLOX study is
a comparison between treatment arms of PFS. Secondary
outcomes will include: PFS in the liver; OS; tumour
response rate (liver and any site); health-related quality of
life (HRQoL); toxicity and safety; and liver resection rate.
Outcome definitions
OS is defined as the time from the date of randomisa-
tion to death from any cause. Patients lost to follow-up,
withdrawn, or alive at study completion will be censored
at the last date that the patient is known to be alive. PFS
is defined as the time from the date of randomisation to
confirmation of disease progression at any site (RECIST
version 1.0 guidelines [25]) or death from any cause ifmab, at the investigator’s discretion, but not until cycle 4.
Figure 2 Treatment received as part of the SIRFLOX study. Figure footnote: ‡Bevacizumab can be added at the investigator’s discretion
starting at cycle 1 (or according to the institutional protocol). †Bevacizumab can be added at the investigator’s discretion but should not be
initiated until cycle 4 (or according to the institutional protocol). If leucovorin is not available, levofolinic acid can be used at a dose of 100 mg/m2. If a
centre considers leucovorin 400 mg/m2 the standard dose, then this will be allowed at the investigator’s discretion. LV = Leucovorin; 5-FU =5-Fluorouracil.
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Patients who change treatment for reasons other than
progression (other than patients who are deemed suit-
able for surgery) will be censored at change of treatment.
PFS and tumour response rate will be determined from
serial CT scans using RECIST version 1.0 criteria. Cen-
tralised assessment of CT scans and tumour response
will be conducted by two independent, board-certified
radiologists. Cases of disagreement in the judgment of
PFS by the two readers will be adjudicated by a medicaloncologist based on both radiological and clinical cri-
teria. The PFS based upon the centralised review consti-
tutes the primary endpoint.
HRQoL will be measured using two questionnaires,
the EQ-5D and the EORTC QLQ-30. Adverse events
(AEs) and Serious Adverse Events (SAEs) will be collected
in accordance with ISO14155 and the International
Conference on Harmonisation (ICH) guidelines, and will
be rated according to Common Terminology Criteria for
Adverse Events (CTCAE) v3.0 and the relationship to
Table 2 Administered dose calculator used in the SIRFLOX study
Percentage tumour involvement
BSA 0-5 6-10 11-15 16-20 21-25 26-30 31-35 36-40 41-45 46-50 51-55 56-60 61-65 66-70 71-75 76-80
0-10% lung breakthrough
1.30-1.35 0.7 0.8 1.0 1.2 1.3 1.4 1.5 1.5 1.5 1.5 1.4 1.3 1.3 1.2 1.1 1.1
1.36-1.40 0.7 0.9 1.0 1.2 1.3 1.4 1.5 1.5 1.5 1.5 1.5 1.4 1.3 1.2 1.2 1.1
1.41-1.45 0.7 0.9 1.1 1.2 1.4 1.5 1.6 1.6 1.6 1.6 1.5 1.4 1.4 1.3 1.2 1.2
1.46-1.50 0.8 0.9 1.1 1.3 1.4 1.5 1.6 1.7 1.7 1.6 1.6 1.5 1.4 1.3 1.3 1.2
1.51-1.55 0.8 1.0 1.1 1.3 1.5 1.6 1.7 1.7 1.7 1.7 1.6 1.5 1.5 1.4 1.3 1.2
1.56-1.60 0.8 1.0 1.2 1.4 1.5 1.6 1.7 1.8 1.8 1.7 1.7 1.6 1.5 1.4 1.3 1.3
1.61-1.65 0.8 1.0 1.2 1.4 1.6 1.7 1.8 1.8 1.8 1.8 1.7 1.6 1.6 1.5 1.4 1.3
1.66-1.70 0.9 1.1 1.3 1.4 1.6 1.7 1.8 1.9 1.9 1.8 1.8 1.7 1.6 1.5 1.4 1.4
1.71-1.75 0.9 1.1 1.3 1.5 1.7 1.8 1.9 1.9 1.9 1.9 1.8 1.7 1.6 1.5 1.5 1.4
1.76-1.80 0.9 1.1 1.3 1.5 1.7 1.8 1.9 2.0 2.0 1.9 1.9 1.8 1.7 1.6 1.5 1.4
1.81-1.85 0.9 1.1 1.4 1.6 1.8 1.9 2.0 2.0 2.0 2.0 1.9 1.8 1.7 1.6 1.5 1.5
1.86-1.90 1.0 1.2 1.4 1.6 1.8 1.9 2.0 2.1 2.1 2.1 2.0 1.9 1.8 1.7 1.6 1.5
1.91-1.95 1.0 1.2 1.4 1.7 1.9 2.0 2.1 2.1 2.1 2.1 2.0 1.9 1.8 1.7 1.6 1.6
1.96-2.00 1.0 1.2 1.5 1.7 1.9 2.1 2.2 2.2 2.2 2.2 2.1 2.0 1.9 1.8 1.7 1.6
2.01-2.05 1.0 1.3 1.5 1.7 1.9 2.1 2.2 2.3 2.3 2.2 2.1 2.0 1.9 1.8 1.7 1.6
2.06-2.10 1.1 1.3 1.6 1.8 2.0 2.2 2.3 2.3 2.3 2.3 2.2 2.1 2.0 1.9 1.8 1.7
2.11-2.15 1.1 1.3 1.6 1.8 2.0 2.2 2.3 2.4 2.4 2.3 2.2 2.1 2.0 1.9 1.8 1.7
2.16-2.20 1.1 1.4 1.6 1.9 2.1 2.3 2.4 2.4 2.4 2.4 2.3 2.2 2.1 1.9 1.8 1.8
2.21-2.25 1.1 1.4 1.7 1.9 2.1 2.3 2.4 2.5 2.5 2.4 2.3 2.2 2.1 2.0 1.9 1.8
2.26-2.30 1.2 1.4 1.7 2.0 2.2 2.4 2.5 2.5 2.5 2.5 2.4 2.3 2.2 2.0 1.9 1.8
2.31-2.35 1.2 1.5 1.7 2.0 2.2 2.4 2.5 2.6 2.6 2.5 2.5 2.3 2.2 2.1 2.0 1.9
2.36-2.40 1.2 1.5 1.8 2.0 2.3 2.5 2.6 2.6 2.6 2.6 2.5 2.4 2.3 2.1 2.0 1.9
2.41-2.45 1.2 1.5 1.8 2.1 2.3 2.5 2.6 2.7 2.7 2.6 2.6 2.4 2.3 2.2 2.0 1.9
2.46-2.50 1.3 1.5 1.8 2.1 2.4 2.6 2.7 2.8 2.8 2.7 2.6 2.5 2.4 2.2 2.1 2.0
11-15% lung breakthrough
1.30-1.35 0.7 0.8 1.0 1.2 1.3 1.4 1.5 1.5 1.5 1.5 1.4 1.3 1.3 1.2 1.1 1.1
1.36-1.40 0.7 0.9 1.0 1.2 1.3 1.4 1.5 1.5 1.5 1.5 1.5 1.4 1.3 1.2 1.2 1.1
1.41-1.45 0.7 0.9 1.1 1.2 1.4 1.5 1.6 1.6 1.6 1.6 1.5 1.4 1.4 1.3 1.2 1.2
1.46-1.50 0.8 0.9 1.1 1.3 1.4 1.5 1.6 1.7 1.7 1.6 1.6 1.5 1.4 1.3 1.3 1.2
1.51-1.55 0.8 1.0 1.1 1.3 1.5 1.6 1.7 1.7 1.7 1.7 1.6 1.5 1.5 1.4 1.3 1.2
1.56-1.60 0.8 1.0 1.2 1.4 1.5 1.6 1.7 1.8 1.8 1.7 1.7 1.6 1.5 1.4 1.3 1.3
1.61-1.65 0.8 1.0 1.2 1.4 1.6 1.7 1.8 1.8 1.8 1.8 1.7 1.6 1.6 1.5 1.4 1.3
1.66-1.70 0.9 1.1 1.3 1.4 1.6 1.7 1.8 1.9 1.9 1.8 1.8 1.7 1.6 1.5 1.4 1.4
1.71-1.75 0.9 1.1 1.3 1.5 1.7 1.8 1.9 1.9 1.9 1.9 1.8 1.7 1.6 1.5 1.5 1.4
1.76-1.80 0.9 1.1 1.3 1.5 1.7 1.8 1.9 2.0 2.0 1.9 1.9 1.8 1.7 1.6 1.5 1.4
1.81-1.85 0.9 1.1 1.4 1.6 1.8 1.9 2.0 2.0 2.0 2.0 1.9 1.8 1.7 1.6 1.5 1.5
1.86-1.90 1.0 1.2 1.4 1.6 1.8 1.9 2.0 2.0 2.0 2.0 2.0 1.9 1.8 1.7 1.6 1.5
1.91-1.95 1.0 1.2 1.4 1.7 1.9 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8 1.7 1.6 1.6
1.96-2.00 1.0 1.2 1.5 1.7 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8 1.7 1.6
2.01-2.05 1.0 1.3 1.5 1.7 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8 1.7 1.6
2.06-2.10 1.1 1.3 1.6 1.8 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8 1.7
2.11-2.15 1.1 1.3 1.6 1.8 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8 1.7
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Table 2 Administered dose calculator used in the SIRFLOX study (Continued)
2.16-2.20 1.1 1.4 1.6 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8 1.8
2.21-2.25 1.1 1.4 1.7 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8
2.26-2.30 1.2 1.4 1.7 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.8
2.31-2.35 1.2 1.5 1.7 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9
2.36-2.40 1.2 1.5 1.8 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9
2.41-2.45 1.2 1.5 1.8 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9
2.46-2.50 1.3 1.5 1.8 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
16-20% lung breakthrough
1.30-1.35 0.7 0.8 1.0 1.2 1.3 1.4 1.5 1.5 1.5 1.5 1.4 1.3 1.3 1.2 1.1 1.1
1.36-1.40 0.7 0.9 1.0 1.2 1.3 1.4 1.5 1.5 1.5 1.5 1.5 1.4 1.3 1.2 1.2 1.1
1.41-1.45 0.7 0.9 1.1 1.2 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.4 1.3 1.2 1.2
1.46-1.50 0.8 0.9 1.1 1.3 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.3 1.3 1.2
1.51-1.55 0.8 1.0 1.1 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.3 1.2
1.56-1.60 0.8 1.0 1.2 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.3 1.3
1.61-1.65 0.8 1.0 1.2 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.3
1.66-1.70 0.9 1.1 1.3 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.4
1.71-1.75 0.9 1.1 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4
1.76-1.80 0.9 1.1 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4
1.81-1.85 0.9 1.1 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
1.86-1.90 1.0 1.2 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
1.91-1.95 1.0 1.2 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
1.96-2.00 1.0 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.01-2.05 1.0 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.06-2.10 1.1 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.11-2.15 1.1 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.16-2.20 1.1 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.21-2.25 1.1 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.26-2.30 1.2 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.31-2.35 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.36-2.40 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.41-2.45 1.2 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
2.46-2.50 1.3 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Dose values are given in GBq.
BSA = Body surface area.
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or probable.
After 360 patients (80% of the intended sample size)
have completed 15 months of follow-up, at least 300
progressions are expected. The actual pooled event rate
will be assessed at this time by an independent data moni-
toring and safety monitoring committee (IDMC) to deter-
mine if the study should continue as planned.
Assessment procedures and timing
All patients will be assessed by the criteria summarised
in Table 3. Additional non-study assessments are permit-
ted at the discretion of the treating investigator.Sample size calculation and statistical considerations
The potential benefit of adding bevacizumab to FOL-
FOX is approximately a 4-week increase in median PFS
[17]. Based on previously reported data, a median PFS
time of 8.5 months may be expected with FOLFOX in pa-
tients with liver-only or liver-dominant mCRC (i.e., in the
control arm); and therefore, with the addition of bevacizu-
mab, median PFS time could be estimated at 9.4 months.
Based on previously reported data of SIRT plus hepatic
artery chemotherapy (median PFS of 16 months [24]) and
SIRT plus first-line 5-FU/LV chemotherapy (median PFS
of 18.6 months [22]), a conservative estimation of median
PFS in the intervention arm would be 15 months for
Table 3 SIRFLOX study assessment schedule
Screening During chemotherapy Post-progression
follow-up
Evaluation/examination (≤28 d before randomisation) Day 1 Day 3 or 4 of cycle 1 Every 2 weeks ±1 weeka (every 12 weeks)
Informed consent X
Demographics X
Medical history X
Concomitant illnesses X
Concurrent medications X X X X
Clinical assessment and
physical examination
X X X
Performance status X X X
Haematologyb X X X
Biochemistryc X X X
Pregnancy test X
Serum CEA X Xd
CT of chest/abdomen/pelvis X Xe X
Assessment for resection X Xe
Hepatic angiogramf Xg
99mTc-MAA lung shunt studyf Xg
Adverse events From consent until 28 days after the last dose of protocol chemotherapy
EQ-5D HRQoL X Xh
EORTC QLQ-C30 HRQoL X Xi
Ongoing review of treatment
and survival
X
aBefore each cycle of chemotherapy unless otherwise stated.
bMeasurement of haemoglobin, platelets, white blood cells, absolute neutrophils and absolute lymphocytes.
cUrea, creatinine, liver enzymes, alkaline phosphatase, bilirubin and albumin.
dEvery 4 weeks.
eEvery 8 weeks.
fIntervention arm only.
g7 days ±4 days before SIRT.
hEQ-5D questionnaire completed at 3, 6, 12, 24, 36 months, and annually thereafter.
i4 weeks and 12 months after starting treatment.
CEA = Carcinoembryonic antigen; CT = Computed tomography.
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patients with liver-dominant metastatic disease. Using
these data and assuming a liver-dominant:liver-only ratio
of 40:60, a sample size of at least 450 patients for the
SIRFLOX study was estimated to detect an increase in
the median PFS from 9.4 months to 12.5 months with
80% power and 95% confidence.
Primary and secondary endpoints will be analysed ac-
cording to the intention-to-treat (ITT) principle. Response
rates will be compared between treatment arms using a
test of proportions, and time to event endpoints will be
compared using the log-rank test. The primary endpoint
will be assessed in the ITT population, and additional ana-
lyses will also assess endpoints in sub-groups: no bevaci-
zumab versus with bevacizumab; presence versus absence
of extra-hepatic metastases; and tumour involvement of
the liver ≤25% versus >25%. Exploratory analyses will beperformed adjusting for prognostic factors in a multivari-
ate analysis framework.
Discussion
The SIRFLOX study will assess the efficacy and safety of
SIRT in combination with FOLFOX-based systemic che-
motherapy as first-line treatment of patients with in-
operable liver-only or liver-predominant mCRC. To date,
efficacy and safety data for this combination are available
in a limited number of patients [23,26], and for the use
of SIRT in chemotherapy-refractory mCRC [27-29]. Al-
though SIRT has been delivered to more than 35,000
patients in over 600 specialist centres worldwide since
2000, such large-scale studies of this treatment have not
been feasible before. However, skilled centres are now
numerous enough worldwide to enable recruitment of a
large pool of patients for these studies.
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study are worth further discussion. The prescribed activity
of SIR-Spheres was determined by the results of the pre-
vious dose-escalation study of SIR-Spheres + FOLFOX4
[23]. Furthermore, in patients randomised to receive SIRT
in the SIRFLOX study, the dose of oxaliplatin is reduced
to 60 mg/m2 for the first three cycles of chemotherapy,
and in subsequent cycles is increased to the standard
dose of 85 mg/m2. One safety concern is that the oxali-
platin in the chemotherapy regimen is a radio-sensitising
agent, which when used in combination with external-
beam radiation therapy results in hepatotoxicity at doses
>60 mg/m2 [30-32]. The earlier dose-escalation study of
SIR-Spheres + FOLFOX4 also concluded that oxaliplatin
at doses >60 mg/m2 in the first three cycles of chemother-
apy could increase the occurrence of grade 3 and 4 neu-
tropenia [23].
mFOLFOX6 chemotherapy has become widely adopted
for the treatment of mCRC, largely because it does not
require the day-2 bolus injections of 5-FU that is part of
FOLFOX4 and is therefore more convenient. Although
previous trials have shown that first-line SIR-Spheres plus
chemotherapy can significantly increase time-to-progression
and survival in patients with mCRC [22,24], these used
chemotherapy regimens that are now outdated in the
management of mCRC. This provides the rationale for
choosing mFOLFOX6 in the study. mFOLFOX6 in-
cludes oxaliplatin doses of 85 mg/m2 rather than the
dose of 100 mg/m2 used in FOLFOX6 [33] – thus, this
will maximise the time that patients can receive protocol
chemotherapy before peripheral neuropathy becomes an
issue (which necessitates the removal of oxaliplatin) [34].
Patient stratification in SIRFLOX includes the intention
to use bevacizumab. The addition of bevacizumab to che-
motherapy regimens may enhance survival times and PFS
in patients with mCRC [17,21,35,36], but little is known
about the potential added benefits of primary chemother-
apy + bevacizumab + SIRT. Data on bevacizumab and the
other biological agents such as cetuximab and panitumu-
mab for the treatment of liver-only mCRC are limited and
sometimes contradictory [37-41], which has made guid-
ance on the optimal first-line treatment strategies difficult
and sometimes conflicting [42]. Indeed, despite the initial
enthusiasm with targeted biological agents and evidence
that they can improve 2-year survival, no gains in 5-year
survival have been observed with these agents [43]. The
approach of combining systemic chemotherapy ± biologic
agents with targeted radiation therapy may provide en-
hanced benefits in mCRC.
Another strata that will be assessed in these trials is the
absence or presence of extra-hepatic metastases. Although
published efficacy data on SIRT and FOLFOX chemother-
apy are limited, initial data did indicate considerably longer
PFS and OS among patients with liver-only disease [26].In addition to the SIRFLOX study, SIRT in combin-
ation with FOLFOX-based systemic chemotherapy as
first-line treatment of patients with inoperable liver-only
or liver-predominant mCRC is being investigated in the
FOXFIRE trial. The studies have almost identical pro-
tocols, and FOXFIRE has as a primary endpoint an a
priori analysis of OS of all patients included in SIRFLOX
and FOXFIRE.
A recent consensus statement on systemic cytotoxic
and biological therapies for liver metastases from CRC
summarised expert recommendations on the management
of patients with non-resectable metastatic tumours [44].
In the accompanying editorial [45], Clary et al. identified
the need to optimise outcomes of systemic treatment
in patients with non-resectable liver metastases as a
key question to be addressed. The SIRFLOX study
and FOXFIRE trial aim to address this issue in a large
patient population and may help provide important
new evidence on the use of SIRT early in the therapeutic
cascade to enhance PFS and/or OS in this patient popula-
tion. The use of SIRT with yttrium-90 resin microspheres
was not specifically addressed in the consensus statement,
presumably due to the paucity of data [44]. Clary et al.
highlighted this omission and concluded, “The optimal
use of these modalities is undefined and requires further
study” [45]. The results from the SIRFLOX study and
FOXFIRE trial should further our understanding of SIRT,
may help define the optimal use of this treatment modality
in mCRC, and may place this treatment option at the fore-
front of future consensus guidelines.Additional file
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